公开(公告)号：US20230279503A1

公开(公告)日：2023-09-07

申请号：US18316719

申请日：2023-05-12

Applicant: Celator Pharmaceuticals, Inc. ,  Oregon Health & Science University

Inventor： Max GORDON ,  Paul TARDI ,  Jeffrey TYNER ,  Lawrence MAYER

IPC: C12Q1/6886 ,  A61K31/5377 ,  A61K31/704 ,  A61K31/7068 ,  C12Q1/68 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/496 ,  A61K31/44 ,  A61K31/506 ,  A61K31/553 ,  A61P35/02 ,  A61K9/127 ,  A61K31/407

CPC classification number: C12Q1/6886 ,  A61K31/5377 ,  A61K31/704 ,  A61K31/7068 ,  C12Q1/68 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/496 ,  A61K31/44 ,  A61K31/506 ,  A61K31/553 ,  A61P35/02 ,  A61K9/127 ,  A61K31/407 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

公开(公告)号：US20230277455A1

公开(公告)日：2023-09-07

申请号：US17960076

申请日：2022-10-04

Applicant: Scynexis, Inc.

Inventor： Rajeshwar Motheram

IPC: A61K9/127 ,  A61K9/00 ,  A61K31/7056

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K9/1277 ,  A61K31/7056

Abstract: Injectable compositions of single bilayer vesicles encapsulating enfumafungin derived triterpenoid antifungal compounds can be administered intravenously to treat or prevent fungal infections, while having reduced local injection site reactions (ISRs). The enfumafungin derived triterpenoid antifungal compounds are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment or prevention of fungal infections, such as systemic fungal infections, including those caused by Candida and Aspergillus species.

公开(公告)号：US11746386B2

公开(公告)日：2023-09-05

申请号：US17173677

申请日：2021-02-11

Applicant: Celator Pharmaceuticals, Inc. ,  Oregon Health & Science University

Inventor： Max Gordon ,  Paul Tardi ,  Jeffrey Tyner ,  Lawrence Mayer

IPC: C12Q1/6886 ,  A61K31/5377 ,  A61K31/704 ,  A61K31/7068 ,  C12Q1/68 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/496 ,  A61K31/44 ,  A61K31/506 ,  A61K31/553 ,  A61P35/02 ,  A61K9/127 ,  A61K31/407

CPC classification number: C12Q1/6886 ,  A61K9/127 ,  A61K31/407 ,  A61K31/44 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7068 ,  A61P35/02 ,  C12Q1/68 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/553 ,  A61K2300/00 ,  A61K31/517 ,  A61K2300/00 ,  A61K31/44 ,  A61K2300/00 ,  A61K31/4709 ,  A61K2300/00 ,  A61K31/506 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00 ,  A61K31/7068 ,  A61K2300/00 ,  A61K31/704 ,  A61K2300/00

Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

公开(公告)号：US11723880B2

公开(公告)日：2023-08-15

申请号：US17470788

申请日：2021-09-09

Applicant: NEXZOL PHARMA, INC.

Inventor： Joseph M. Fracassi ,  Thomas J. Scarlata

IPC: A61K31/05 ,  A61K9/00 ,  A61K9/06 ,  A61K9/127 ,  A61K9/50 ,  A61K47/18 ,  A61K47/58 ,  A61K47/36 ,  A61P37/02

CPC classification number: A61K31/05 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/127 ,  A61K9/5005 ,  A61K47/183 ,  A61K47/36 ,  A61K47/58 ,  A61P37/02

Abstract: Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation.

公开(公告)号：US20230241091A1

公开(公告)日：2023-08-03

申请号：US18173980

申请日：2023-02-24

Applicant: Henry Ford Health System

Inventor： Jieli CHEN ,  Michael CHOPP

IPC: A61K31/7105 ,  A61P9/04 ,  A61K9/00 ,  A61K9/127

CPC classification number: A61K31/7105 ,  A61P9/04 ,  A61K9/0019 ,  A61K9/127

Abstract: Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.

公开(公告)号：US20230233605A1

公开(公告)日：2023-07-27

申请号：US17964100

申请日：2022-10-12

Applicant: Peking University School and Hospital of Stomatology

Inventor： Hao Liu ,  Yongsheng Zhou ,  Wei Li ,  Ranli Gu

IPC: A61K35/16 ,  A61K9/127 ,  A61P19/08

CPC classification number: A61K35/16 ,  A61K9/127 ,  A61P19/08

Abstract: A serum exosome with high osteogenesis and high angiogenesis, a preparation method and an application thereof are provided, which belongs to the field of bone defect repair technologies. The serum exosome is derived from a serum in a fracture recovery period, and the fracture recovery period is in a range of a second week to a fifth week after fracture. It has been found that the exosomes extracted from the serum after fracture have stronger osteogenic and angiogenic properties than exosomes extracted from normal serum, which is helpful to solve problems that large segmental bone defects, extensive traumas and other diseases are difficult to repair, and provide a new therapy for all diseases that need to be repaired and cured through osteogenic and/or angiogenic properties.

公开(公告)号：US20230218746A1

公开(公告)日：2023-07-13

申请号：US18001561

申请日：2021-06-15

Applicant: NORTH CAROLINA STATE UNIVERSITY

Inventor： Ke Cheng ,  Phuong-Uyen Cao Dinh ,  Zhenhua Li

IPC: A61K39/215 ,  A61K35/42 ,  A61K38/48 ,  A61K38/17 ,  A61K9/127 ,  A61K31/675 ,  A61K38/21 ,  A61K31/513 ,  A61K31/427 ,  A61P31/14

CPC classification number: A61K39/215 ,  A61K35/42 ,  A61K38/4813 ,  A61K38/1709 ,  A61K38/177 ,  A61K9/127 ,  A61K31/675 ,  A61K38/215 ,  A61K31/513 ,  A61K31/427 ,  A61P31/14 ,  A61K2039/5156

Abstract: The present disclosure provides compositions and methods related to antiviral therapeutics. In particular, the present disclosure provides novel compositions and methods for treating and/or preventing viral infections using vesicles derived from lung spheroid cells (LSCs). LSC-derived vesicles can be used as viral decoy nanoparticles for therapeutic applications, as virus-like particles (VLPs) for vaccine production, and as an antiviral drug delivery platform.

公开(公告)号：US20230210771A1

公开(公告)日：2023-07-06

申请号：US18001089

申请日：2021-06-08

Applicant: DISRUPTION LABS INC.

Inventor： Brian R. SLOAT ,  Michael A SANDOVAL

IPC: A61K9/127 ,  A61K31/05 ,  A61K45/06 ,  A61K31/015 ,  A61K47/28 ,  A61K47/24 ,  A61K47/14

CPC classification number: A61K9/127 ,  A61K31/05 ,  A61K45/06 ,  A61K31/015 ,  A61K47/28 ,  A61K47/24 ,  A61K47/14 ,  B82Y5/00

Abstract: Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of therapeutic agents to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

公开(公告)号：US11690809B2

公开(公告)日：2023-07-04

申请号：US16783430

申请日：2020-02-06

Applicant: Emek Blair

Inventor： Emek Blair

IPC: A61K36/185 ,  A61K31/05 ,  A61K9/127 ,  A61K9/00 ,  A61P3/10 ,  A61K9/107

CPC classification number: A61K31/05 ,  A61K9/0053 ,  A61K9/1075 ,  A61K9/127 ,  A61K36/185 ,  A61P3/10

Abstract: A method of treating or alleviating symptoms of a disorder or a condition in a subject, including identifying the disorder or the condition of a subject, the disorder or condition identified based on first measures of a bloodstream concentration of a substance or a blood stream count of cellular elements, orally administering to said subject an amount of cannabidiol over a period of time effective treat or alleviate symptoms of said disorder or said condition, altering the bloodstream concentration of said substance or said blood stream count of cellular elements, and assessing efficacy of treating or alleviating symptoms of the disorder or the condition evidenced by comparing second measures of the bloodstream concentration of the substance or the blood stream count of cellular elements after the period time to the first measures of bloodstream concentration of the substance or the blood stream count of cellular elements.

公开(公告)号：US20230201370A1

公开(公告)日：2023-06-29

申请号：US18057359

申请日：2022-11-21

Applicant: Evox Therapeutics Ltd. ,  Oxford University Innovation Limited

Inventor： Justin HEAN ,  Imre MAGER ,  Matthew WOOD ,  Samir EL ANDALOUSSI ,  Oscar WIKLANDER ,  Joel NORDIN

IPC: A61K48/00 ,  A61K47/65 ,  A61K41/00 ,  A61K47/64 ,  A61K47/00 ,  A61K9/127

CPC classification number: A61K48/0008 ,  A61K47/65 ,  A61K41/0042 ,  A61K47/6425 ,  A61K47/00 ,  A61K9/127 ,  A61K48/005 ,  A61K48/0091

Abstract: The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.